mAbxience

Executive Summary

mAbxience is a vertically integrated biotechnology company specializing in biosimilar monoclonal antibodies and biologics, with a global CDMO platform. Founded in 2007 and headquartered in Zug, Switzerland, the company provides end-to-end services from R&D to commercial production. While mAbxience has no publicly disclosed pipeline or approved products, it positions itself as a key player in the biosimilar space, leveraging its manufacturing capabilities to serve both proprietary and client programs. The biosimilar market is growing, driven by patent expirations and cost containment in healthcare. However, mAbxience faces intense competition from larger players and must execute on regulatory approvals and commercial launches to generate revenue. Its CDMO business provides a more stable revenue stream, but profitability depends on utilization rates and contract wins. The company's private status limits visibility into financials, but its focus on high-barrier biologics manufacturing suggests potential for long-term value creation if it secures partnerships or advances its own biosimilar pipeline.

Upcoming Catalysts (preview)

• Q4 2026FDA or EMA approval of a lead biosimilar candidate40% success
• H2 2026Major CDMO contract win with a large pharma partner60% success
• Q3 2026Manufacturing capacity expansion announcement70% success